CCNE1 overexpression is in agreement with the highly significant cell-cycle pathway that the gene set enrichment analysis placed on rank 3 ( Supplemental Table 5 ).
← all excerpts
Metastatic triple-negative breast cancer patient with <i>TP53</i> tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
1
—
—